← Back to Search

Unknown

BMS-986278 for Pulmonary Fibrosis

Phase 2

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at weeks 4, 8, 12, 16, 20, and 26

Awards & highlights

Study Summary

This trial is to study the effects of BMS-986278 on people with lung fibrosis and to see if it is safe.

Eligible Conditions

Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at weeks 4, 8, 12, 16, 20, and 26

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at weeks 4, 8, 12, 16, 20, and 26

This trial's timeline: 3 weeks for screening, Varies for treatment, and at weeks 4, 8, 12, 16, 20, and 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of change in percent predicted forced vital capacity(ppFVC) in Idiopathic Pulmonary Fibrosis (IPF) Participants

Secondary outcome measures

Absolute change in FVC (mL) from baseline to Week 26

Absolute change in ppDLCO SB (%) (corrected for hemoglobin) from baseline to Week 26

Absolute change in ppFVC (%) from baseline to Week 26

+28 more

Trial Design

6Treatment groups

Experimental Treatment

Placebo Group

Group I: PF-ILD Dose 2 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention

Group II: PF-ILD Dose 1 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention

PF-ILD (Progressive Fibrotic Interstitial Lung Disease)

Group III: IPF Dose 2 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention

Group IV: IPF Dose 1 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention

IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)

Group V: PF-ILD Placebo + Post Treatment Follow-up or OTEPlacebo Group1 Intervention

Group VI: IPF Placebo + Post Treatment Follow-up or OTEPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BMS-986278

2023

Completed Phase 2

~750

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,115 Total Patients Enrolled

6 Trials studying Pulmonary Fibrosis

2,738 Patients Enrolled for Pulmonary Fibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients still being accepted into this research project?

"This particular clinical trial, which was first announced on July 29th 2020, is not currently looking for new participants. However, there are other 436 trials that are actively recruiting patients."

Answered by AI

Is BMS-986278 a danger to human health?

"BMS-986278 falls into the category of a Phase 2 trial drug, so there is some evidence to support its safety, but not necessarily its efficacy. Our team at Power gave it a score of 2."

Answered by AI

In how many different medical clinics is this medical study being run today?

"There are 36 hospitals participating in this trial, such as the University of Virginia Health System-Division of Pulmonary and Critical Care Medicine in Montreal, Washington University School Of Medicine in Salt Lake City, and University of Cincinnati Medical Center-Division of Pulmonary, Critical Care and Sleep Medicine in Austell."

Answered by AI